Amy Webb

Supplemental Figure S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Figure S1: Enhanced Risk Estimate Participant Reports.

Supplemental Materials S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Materials S2. Survey Scoring.

Supplemental Table S5 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S5. Representativeness of Study Participants.

Supplemental Table S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S2. SNVs and weights used for BRCA2 88-SNV Breast PRS model.

Supplemental Table S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S1. SNVs and weights used for BRCA1 ER- 53-SNV Breast PRS Model.

Supplemental Materials S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Materials S1. Baseline and Follow-up Survey Questions.

Supplemental Table S4 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S4. SNVs and weights used for BRCA2 Ovarian PRS model.

Supplemental Table S6 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S6. Comparison of GRE and 313-SNV breast cancer risks.

Supplemental Table S3 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Supplemental Table S3. SNVs and weights used for BRCA1 Ovarian PRS model.

Data from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Lauren Norden et autres

Abstract Individuals with germline BRCA1 or BRCA2 pathogenic variants (PV) may struggle with risk management decision-making. Advancements in technology could provide more specific risk information to patients, but the impact of this information is unknown. The Clinical Application of Refined Risk Estimates …

The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial

Leigha Senter, Shelly Renee Anstey Hovick, Rachel Notestine, Norden Lc et autres

Individuals with germline BRCA1 or BRCA2 pathogenic variants (PV) may struggle with risk management decision-making. Advancements in technology could provide more specific risk information to patients, but the impact of this information is unknown. The Clinical Application of Refined Risk Estimates Study …

us (code pays fourni par la source)

Alternatively activated neutrophils limit T cell–driven neuroinflammation

Jeffrey R. Atkinson, Calli E. Bellinger, Andrew David Jerome, Ashley Munie Gardner et autres

OBJECTIVE: Non-canonical myeloid cell populations are increasingly recognized as critical regulators of inflammation in neuroimmunological disease. Here, we investigate the role of alternatively activated neutrophils (aaN) in limiting encephalitogenic T cell responses during experimental autoimmune encephalomyelitis (EAE), a widely used model of …

us (code pays fourni par la source)